Tirzep®-Tirzepatide Injection [ACI – Bangladesh]

Tirzep® (Tirzepatide) Injection | Dual GIP/GLP-1 Agonist for Obesity & Metabolic Research

Category: Peptides → Dual Incretin Agonists / Weight Loss / Type 2 Diabetes
Keyphrase: Tirzepatide Injection
Purity: ≥99% (HPLC)
Format: Prefilled Injection Pen
Edition: ACI Bangladesh Edition

🔬 What is Tirzep® (Tirzepatide)?

Tirzep®, developed by ACI Pharmaceuticals (Bangladesh), contains the breakthrough peptide Tirzepatide—a first-in-class dual GIP and GLP-1 receptor agonist. Its ability to engage both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors offers superior metabolic modulation compared to single-pathway incretin therapies.

Tirzep® is provided in a prefilled subcutaneous injection pen, designed for ease of use in preclinical models focused on obesity, insulin resistance, type 2 diabetes, and cardiometabolic disorders.

🧪 Product Specifications

• Synonyms: Tirzepatide, LY3298176

• Molecular Formula: C225H348N48O68

• Molecular Weight: ~4813.5 g/mol

• Form: Prefilled injection pen

• Purity: ≥99% (HPLC)

• Edition: ACI Bangladesh Market Research Version

• Storage: 2–8°C, refrigerate and protect from light

🧬 Key Research Applications

• Obesity & Weight Loss Studies
  Demonstrates significant reductions in body weight, adiposity, and food intake

• Type 2 Diabetes Research
  Improves glycemic control, insulin sensitivity, and beta-cell function

• Incretin Signaling Pathway Models
  Enables investigation into GIP/GLP-1 synergy on metabolic regulation

• Liver Fat & Cardiovascular Risk Reduction
  Shown to lower liver triglyceride content and improve lipid profiles in animal models

📚 Supporting Scientific Literature

1. Tirzepatide in Obesity and Diabetes Research
   NEJM, 2022 – SURMOUNT-1 Study

2. Dual Incretin Pathways for Metabolic Disease
   Nature Reviews Endocrinology, 2022

3. Insulin Sensitization and Appetite Regulation with Tirzepatide
   Diabetes Care, 2021

🔗 Related Compounds

• Ozempic (Semaglutide) – GLP-1 analog for weekly dosing

• Retatrutide – Triple agonist for obesity and liver research

• Saxenda (Liraglutide) – Daily GLP-1 analog for satiety studies

⚠️ For Research Use Only

This product is intended exclusively for in vitro, preclinical, or formulation research purposes. It is not approved for human use, diagnostics, or therapeutic applications.